N Z Med J. 2025 Nov 21;138(1626):49-61. doi: 10.26635/6965.6989.
ABSTRACT
AIM: We investigated Māori and Pacific adults with type 2 diabetes (T2D) to determine the prevalence of latent autoimmune diabetes in adults (LADA), assess the type 1 diabetes (T1D) genetic risk score (GRS) distribution in those with and without autoantibodies and investigate differences in clinical diabetes characteristics based on autoantibody presence or a high T1D GRS.
METHOD: A total of 2,538 Māori and Pacific participants from the Genetics of Gout, Diabetes, and Kidney Disease study in Aotearoa New Zealand were included (830 with T2D, 1,708 without). LADA was defined as age of diabetes onset >30 years, presence of autoantibodies and no insulin treatment within the first 6 months. Clinical characteristics were extracted from medical records. T1D-associated autoantibodies (glutamic acid decarboxylase, islet antigen 2, zinc transporter 8) were measured from stored blood samples from 293 participants (262 T2D, 31 without). A T1D GRS consisting of 30 single-nucleotide polymorphisms was calculated for all participants.
RESULTS: Autoantibodies were detected in 8.8% (23/262) of individuals with T2D, with 5.3% (14/262) meeting the criteria for LADA. No significant difference in T1D GRS or clinical characteristics was observed between T2D cases with and without autoantibodies. Autoantibodies were also detected in 3.2% (1/31) of participants without diabetes.
CONCLUSION: LADA is present in a subset of Māori and Pacific individuals with T2D. Autoantibody presence was not associated with differences in T1D GRS or clinical features. Further research is needed to assess whether C-peptide monitoring could guide treatment decisions in those with LADA.
PMID:41264820 | DOI:10.26635/6965.6989
